Eosinophils in COPD: just another biomarker?

The Lancet Respiratory Medicine

Volumn 5, Issue 9, 2017, Pages 747-759

  Bafadhel, Mona ^a   Pavord, Ian D ^a   Russell, Richard E K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; BRONCHODILATING AGENT;

ASTHMA; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; CYTOLOGY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; EOSINOPHIL; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; INNATE IMMUNITY; LEUKOCYTE FUNCTION; LUNG PARENCHYMA; MORTALITY; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMIC THERAPY; TREATMENT RESPONSE; BLOOD; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; RISK FACTOR;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BIOMARKERS; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; EOSINOPHILS; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE COUNT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 85020453624     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30217-5     Document Type: Review

References (114)

1. Hallstrand, TS, Henderson, WR, An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 10 (2010), 60–66.
2. MacDonald, AS, Araujo, MI, Pearce, EJ, Immunology of parasitic helminth infections. Infect Immun 70 (2002), 427–433.
3. Lee, JJ, Dimina, D, Macias, MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305 (2004), 1773–1776.
4. Mesnil, C, Raulier, S, Paulissen, G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest 126 (2016), 3279–3295.
5. Wong, CK, Cheung, PF, Ip, WK, Lam, CW, Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol 37 (2007), 85–96.
6. Bafadhel, M, McKenna, S, Terry, S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184 (2011), 662–671.
7. Bafadhel, M, McKenna, S, Terry, S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 186 (2012), 48–55.
8. Pascoe, S, Locantore, N, Dransfield, MT, Barnes, NC, Pavord, ID, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
9. Siddiqui, SH, Guasconi, A, Vestbo, J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 523–525.
10. Watz, H, Tetzlaff, K, Wouters, EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 4 (2016), 390–398.
11. Pavord, ID, Lettis, S, Locantore, N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 71 (2016), 118–125.
12. Ehrlich, P, Über die specifischen granulationen des blutes. Arch Anat Physiol 3 (1879), 571–579.
13. Rosenberg, HF, Dyer, KD, Foster, PS, Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13 (2013), 9–22.
14. Chu, DK, Jimenez-Saiz, R, Verschoor, CP, et al. Indigenous enteric eosinophils control DCs to initiate a primary Th2 immune response in vivo. J Exp Med 211 (2014), 1657–1672.
15. Müller, E, Localization of eosinophils in the thymus by the peroxidase reaction. Histochemistry 52 (1977), 273–279.
16. Pégorier, S, Wagner, LA, Gleich, GJ, Pretolani, M, Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. J Immunol 177 (2006), 4861–4869.
17. Fredens, K, Dahl, R, Venge, P, The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol 70 (1982), 361–366.
18. Séguéla, PE, Iriart, X, Acar, P, Montaudon, M, Roudaut, R, Thambo, JB, Eosinophilic cardiac disease: molecular, clinical and imaging aspects. Arch Cardiovasc Dis 108 (2015), 258–268.
19. Wang, JG, Mahmud, SA, Thompson, JA, Geng, JG, Key, NS, Slungaard, A, The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 107 (2006), 558–565.
20. Wardlaw, AJ, Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 104 (1999), 917–926.
21. Lilly, CM, Nakamura, H, Kesselman, H, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 99 (1997), 1767–1773.
22. Spencer, LA, Weller, PF, Eosinophils and Th2 immunity: contemporary insights. Immunol Cell Biol 88 (2010), 250–256.
23. Stehle, C, Saikali, P, Romagnani, C, Putting the brakes on ILC2 cells. Nat Immunol 17 (2016), 43–44.
24. Fulkerson, PC, Rothenberg, ME, Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 12 (2013), 117–129.
25. Hällgren, R, Venge, P, Cullhed, I, Olsson, I, Blood eosinophils and eosinophil cationic protein after acute myocardial infarction or corticosteroid administration. Br J Haematol 42 (1979), 147–154.
26. Oda, H, Kawayama, T, Imaoka, H, et al. Interleukin-18 expression, CD8(+) T cells, and eosinophils in lungs of nonsmokers with fatal asthma. Ann Allergy Asthma Immunol 112 (2014), 23–28.
27. Lacoste, JY, Bousquet, J, Chanez, P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 92 (1993), 537–548.
28. Bal, SM, Bernink, JH, Nagasawa, M, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol 17 (2016), 636–645.
29. Ahren, IL, Eriksson, E, Egesten, A, Riesbeck, K, Nontypeable Haemophilus influenzae activates human eosinophils through beta-glucan receptors. Am J Respir Cell Mol Biol 29 (2003), 598–605.
30. Clemans, DL, Bauer, RJ, Hanson, JA, et al. Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae. Infect Immun 68 (2000), 4430–4440.
31. Torrent, M, Navarro, S, Moussaoui, M, Nogues, MV, Boix, E, Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 47 (2008), 3544–3555.
32. Rosenberg, HF, Dyer, KD, Domachowske, JB, Respiratory viruses and eosinophils: exploring the connections. Antiviral Res 83 (2009), 1–9.
33. Handzel, ZT, Busse, WW, Sedgwick, JB, et al. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol 160 (1998), 1279–1284.
34. Bousquet, J, Chanez, P, Lacoste, JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 323 (1990), 1033–1039.
35. Messer, JW, Peters, GA, Bennett, WA, Causes of death and pathologic findings in 304 cases of bronchial asthma. Dis Chest 38 (1960), 616–624.
36. Green, RH, Brightling, CE, McKenna, S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
37. Green, RH, Brightling, CE, Woltmann, G, Parker, D, Wardlaw, AJ, Pavord, ID, Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57 (2002), 875–879.
38. Gudbjartsson, DF, Bjornsdottir, US, Halapi, E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 41 (2009), 342–347.
39. Haldar, P, Brightling, CE, Hargadon, B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
40. Bel, EH, Ortega, HG, Pavord, ID, Glucocorticoids and mepolizumab in eosinophilic asthma. N Engl J Med, 371, 2014, 2434.
41. Ortega, HG, Liu, MC, Pavord, ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
42. Pavord, ID, Korn, S, Howarth, P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
43. Saha, S, Brightling, CE, Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 1 (2006), 39–47.
44. Bafadhel, M, McCormick, M, Saha, S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 83 (2012), 36–44.
45. Rutgers, SR, Timens, W, Kaufmann, HF, van der Mark, TW, Koeter, GH, Postma, DS, Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 15 (2000), 109–115.
46. Zhu, J, Bandi, V, Qiu, S, et al. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest 142 (2012), 347–357.
47. Ikeda, G, Miyahara, N, Koga, H, et al. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Am J Respir Cell Mol Biol 50 (2014), 18–29.
48. Rubinstein, I, Kumar, B, Schriever, C, Long-term montelukast therapy in moderate to severe COPD—a preliminary observation. Respir Med 98 (2004), 134–138.
49. Miller, M, Ramsdell, J, Friedman, PJ, Cho, JY, Renvall, M, Broide, DH, Computed tomographic scan-diagnosed chronic obstructive pulmonary disease-emphysema: eotaxin-1 is associated with bronchodilator response and extent of emphysema. J Allergy Clin Immunol 120 (2007), 1118–1125.
50. Sze, MA, Dimitriu, PA, Suzuki, M, et al. Host response to the lung microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 438–445.
51. Wang, Z, Bafadhel, M, Haldar, K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 47 (2016), 1082–1092.
52. Silver, JS, Kearley, J, Copenhaver, AM, et al. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol 17 (2016), 626–635.
53. Crellin, NK, Trifari, S, Kaplan, CD, Satoh-Takayama, N, Di Santo, JP, Spits, H, Regulation of cytokine secretion in human CD127(+) LTi-like innate lymphoid cells by toll-like receptor 2. Immunity 33 (2010), 752–764.
54. Percopo, CM, Dyer, KD, Ochkur, SI, et al. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood, 123, 2014, 743.
55. Linch, SN, Kelly, AM, Danielson, ET, Pero, R, Lee, JJ, Gold, JA, Mouse eosinophils possess potent antibacterial properties in vivo. Infect Immun 77 (2009), 4976–4982.
56. Eltboli, O, Bafadhel, M, Hollins, F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med, 14, 2014, 112.
57. Brightling, CE, Bleecker, ER, Panettieri, RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2 (2014), 891–901.
58. Sin, DD, Miravitlles, M, Mannino, DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 48 (2016), 664–673.
59. Siva, R, Green, RH, Brightling, CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 29 (2007), 906–913.
60. Bathoorn, E, Liesker, J, Postma, DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis 4 (2009), 101–109.
61. Anand, A, Ahmed, O, Pavord, ID, McClure, M, Ferry, B, Pavord, SR, Blood eosinophil counts in normal controls with no history of allergic disease. Thorax, 70, 2015, A111 (abstr).
62. Eltboli, O, Bafadhel, M, Pavord, ID, Chiodini, P, Brightling, CE, Eosinophilic chronic obstructive pulmonary disease is not associated with helminth infection or exposure. J Pulm Respir Med, 4, 2014, 179.
63. Singh, D, Kolsum, U, Brightling, CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 44 (2014), 1697–1700.
64. Hastie, AT, Alexis, NE, Doerschuk, C, et al. Blood eosinophils poorly correlate with sputum eosinophils, and have few associations with spirometry, clinical and quantitated computed tomography measures compared to sputum eosinophils in the SPIROMICS cohort. Am J Respir Crit Care Med, 193, 2016, A6168.
65. Bafadhel, M, McKenna, S, Pickering, S, et al. The sensitivity and specificity of peripheral blood eosinophilia to predict sputum eosinophilia in COPD subjects. Am J Respir Crit Care Med, 179, 2009, A1479 (abstr).
66. Negewo, N, McDonald, V, Baines, K, et al. Can blood eosinophils predict sputum eosinophils in stable COPD?. Eur Respir J, 46(suppl 59), 2015, PA3967.
67. WHO. Biomarkers in risk assessment: validity and validation, 2001, World Health Organization, Geneva http://www.inchem.org/documents/ehc/ehc/ehc222.htm (accessed March 12, 2017).
68. Brightling, CE, Monterio, W, Green, RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med 95 (2001), 999–1002.
69. Beeh, KM, Beier, J, Kornmann, O, Mander, A, Buhl, R, Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPDa. Chest 123 (2003), 778–783.
70. Hurst, JR, Vestbo, J, Anzueto, A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
71. Britton, J, Pavord, I, Richards, K, et al. Factors influencing the occurrence of airway hyperreactivity in the general population: the importance of atopy and airway calibre. Eur Respir J, 7, 1994, 881.
72. Hospers, JJ, Schouten, JP, Weiss, ST, Rijcken, B, Postma, DS, Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 160 (1999), 1869–1874.
73. Hospers, JJ, Postma, DS, Rijcken, B, Weiss, ST, Schouten, JP, Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 356 (2000), 1313–1317.
74. Hospers, JJ, Rijcken, B, Schouten, JP, Postma, DS, Weiss, ST, Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol 150 (1999), 482–491.
75. Hospers, JJ, Schouten, JP, Weiss, ST, Postma, DS, Rijcken, B, Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology 11 (2000), 261–268.
76. Vedel-Krogh, S, Nielsen, SF, Lange, P, Vestbo, J, Nordestgaard, BG, Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 193 (2016), 965–974.
77. Barnes, NC, Sharma, R, Lettis, S, Calverley, PM, Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 47 (2016), 1374–1382.
78. Rogliani, P, Puxeddu, E, Ciaprini, C, et al. The time course of pulmonary function tests in COPD patients with different levels of blood eosinophils. Biomed Res Int, 2016, 2016, 4547953.
79. Snoeck-Stroband, JB, Lapperre, TS, Sterk, PJ, et al. Prediction of long-term benefits of inhaled steroids by phenotypic markers in moderate-to-severe COPD: a randomized controlled trial. PLoS One, 10, 2015, e0143793.
80. Shim, C, Stover, DE, Williams, MH Jr, Response to corticosteroids in chronic bronchitis. J Allergy Clin Immunol 62 (1978), 363–367.
81. Leigh, R, Pizzichini, MM, Morris, MM, Maltais, F, Hargreave, FE, Pizzichini, E, Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 27 (2006), 964–971.
82. Pizzichini, E, Pizzichini, MM, Gibson, P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 158 (1998), 1511–1517.
83. Brightling, CE, McKenna, S, Hargadon, B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60 (2005), 193–198.
84. Price, D, West, D, Brusselle, G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 9 (2014), 889–904.
85. 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388 (2016), 963–973.
86. Calverley, PM, Boonsawat, W, Cseke, Z, Zhong, N, Peterson, S, Olsson, H, Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003), 912–919.
87. Calverley, P, Pauwels, R, Vestbo, J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003), 449–456.
88. Dransfield, MT, Bourbeau, J, Jones, PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1 (2013), 210–223.
89. Wedzicha, JA, Singh, D, Vestbo, J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med 108 (2014), 1153–1162.
90. Burge, PS, Calverley, PM, Jones, PW, Spencer, S, Anderson, JA, Maslen, TK, Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000), 1297–1303.
91. Wedzicha, JA, Calverley, PM, Seemungal, TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008), 19–26.
92. Calverley, PM, Anderson, JA, Celli, B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
93. Vestbo, J, Anderson, JA, Brook, RD, et al., SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387 (2016), 1817–1826.
94. Suissa, S, Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 68 (2013), 540–543.
95. Janson, C, Larsson, K, Lisspers, KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ, 346, 2013, f3306.
96. Suissa, S, Patenaude, V, Lapi, F, Ernst, P, Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68 (2013), 1029–1036.
97. Magnussen, H, Disse, B, Rodriguez-Roisin, R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371 (2014), 1285–1294.
98. Zhong, N, Wang, C, Zhou, X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 10 (2015), 1015–1026.
99. Vogelmeier, CF, Bateman, ED, Pallante, J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 1 (2013), 51–60.
100. Wedzicha, JA, Price, D, Mezzi, K, Fogel, R, Banerji, D, QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: a pooled analysis of LANTERN and ILLUMINATE. Eur Respir J, 46, 2015, PA1005 (abstr).
101. Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
102. Seemungal, TA, Donaldson, GC, Bhowmik, A, Jeffries, DJ, Wedzicha, JA, Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000), 1608–1613.
103. Donaldson, GC, Seemungal, TA, Bhowmik, A, Wedzicha, JA, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002), 847–852.
104. Connors, AF Jr, Dawson, NV, Thomas, C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154 (1996), 959–967.
105. Anthonisen, NR, Manfreda, J, Warren, CP, Hershfield, ES, Harding, GK, Nelson, NA, Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987), 196–204.
106. Rodriguez-Roisin, R, Toward a consensus definition for COPD exacerbations. Chest 117:suppl 2 (2000), 398S–401S.
107. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 global strategy for diagnosis, management and prevention of COPD, 2017 http://goldcopd.org (accessed March 12, 2017).
108. Saetta, M, Di Stefano, A, Maestrelli, P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150 (1994), 1646–1652.
109. Bathoorn, E, Liesker, J, Postma, DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis 4 (2009), 101–109.
110. Bafadhel, M, Davies, L, Calverley, PM, Aaron, SD, Brightling, CE, Pavord, ID, Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 44 (2014), 789–791.
111. Couillard, S, Larivee, P, Courteau, J, Vanasse, A, Eosinophils in COPD exacerbations are associated with increased readmissions. Chest 151 (2017), 366–373.
112. Bafadhel, M, Greening, NJ, Harvey-Dunstan, TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 150 (2016), 320–328.
113. Holland, M, Alkhalil, M, Chandromouli, S, Janjua, A, Babores, M, Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology 15 (2010), 165–167.
114. Steer, J, Gibson, J, Bourke, SC, The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 67 (2012), 970–976.